Active substance
Anti d immunoglobulin
- SFDA 4
- Health Canada 2
- WHO EML 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RHOPHYLAC 300MCG-2ML SOL. FOR INJ.IN PFS | 300 µg | Solution for injection · Intravenous use | 1 Injection Syringe | SAR 228.75 | Biological · Prescription | CSL BEHRING | Valid |
| D-GAM 250IU VIAL | 250 IU/ml | Solution for injection · Intravenous use | 1 Vial | SAR 132.80 | Biological · Prescription | BIO-PRODUCT LAB | Withdrawn by MAH · Not Marketed |
| PARTOBULIN SDF 1250 I.U-MLPRELOADED SYR. | 1250 IU/ml | Solution · Intravenous use | 1 Pre-filled syringe | SAR 246.00 | Biological · Prescription | Takeda Manufacturing AG | Withdrawn by MAH · Not Marketed |
| RHESONATIVE 250 MCG-2ML VIAL | 125 µ/ml | Injection · Intravenous use | 1 Vial | SAR 102.40 | Biological · Prescription | OCTAPHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
IMMUNE THROMBOCYPTOPENIC PUPURA; MATERNAL AND CHILD HEALTHCARE-UNEXPLAINED VAGINAL BLEEDING AFTER 13 WEEKS
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| WINRHO SDF | 02302551 | 600 UNIT / VIAL | SOLUTION · INTRAVENOUS; INTRAMUSCULAR | KI BIOPHARMA LLC |
| WINRHO SDF | 02302578 | 1500 UNIT / VIAL | SOLUTION · INTRAMUSCULAR; INTRAVENOUS | KI BIOPHARMA LLC |
WHO WHO Model List of Essential Medicines (2025)
- 11.2. Human immunoglobulins · core
Maternal care for red cell antibodies; Rh incompatibility reaction
Parenteral > General injections > IV: 250 µg in single-dose vial | Parenteral > General injections > IM: 250 µg in single-dose vial
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.